Palvella Therapeutics
PVLA
66 hedge funds and large institutions have $130M invested in Palvella Therapeutics in 2017 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 5 closing their positions.
340% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 5
70% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 10
35% more funds holding
Funds holding: 49 → 66 (+17)
14% more capital invested
Capital invested by funds: $114M → $130M (+$16.3M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.02% less ownership
Funds ownership: 0.65% → 0.64% (-0.02%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $95K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.5M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$1.15M |
| 3 |
Millennium Management
New York
|
+$1.1M |
| 4 |
Cerity Partners
New York
|
+$856K |
| 5 |
JP Morgan Chase
New York
|
+$545K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$3.66M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$2.7M |
| 3 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$871K |
| 4 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$712K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$534K |
PVLA Hedge Fund Activity: Q3 2017 in Review
66 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q3 2017, worth a combined $130M — up 14% from $114M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new PVLA positions and 5 closed out — a net gain of 17 holders — while 17 added to existing stakes and 10 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $1.5M. The largest seller was Lombard Odier Asset Management (USA), cutting an estimated $3.66M.
- 66 institutional investors held Palvella Therapeutics (PVLA) as of Q3 2017, up from 49 in Q2 2017.
- Funds reported $130M of Palvella Therapeutics stock for Q3 2017, up 14% quarter-over-quarter.
- 22 funds opened new Palvella Therapeutics positions in Q3 2017 and 5 closed out, a net change of +17 holders.
- The largest Palvella Therapeutics buyer in Q3 2017 was Renaissance Technologies, an estimated $1.5M added.
- The largest Palvella Therapeutics seller in Q3 2017 was Lombard Odier Asset Management (USA), an estimated $3.66M sold.
Based on aggregated 13F filings for Q3 2017.